Proteins are essential for life. Every cell in our body makes protein every day. And for those proteins to work correctly, they need to fold in a certain three-dimensional shape and space. Systems in our cells recognize misshapen proteins and try to fix them. If they can’t help fold them into the correct shape, the […]
March is Amyloidosis Awareness Month, and at Prothena we believe it’s important to shine light on firsthand perspectives from people directly impacted by the disease. In this video, Linda offers advice to those affected by AL amyloidosis. Whether advice for others impacted by the disease, the journey to diagnosis, or working together with a care […]
AL amyloidosis is a rare, progressive and life-threatening disease that leads to the production and aggregation of misfolded toxic light chain proteins. These aggregates cause problems in the body’s circulation, depositing in the heart and kidney, leading to damage and organ failure. Patients often present with a wide range of general symptoms that are common […]
February 29, 2024 marks Rare Disease Day, and we’re honored to hear from Donna-Lee about the importance of this day and her personal connection to rare disease. Check out the video below and hear from more Prothenians on why they care about rare here. Earlier this month, we celebrated International Day of Women […]
From selecting appropriate patients for clinical studies, to identifying the right endpoints and biomarkers, 2023 was marked with the very first disease-modifying treatments for Alzheimer’s disease. Looking ahead in 2024, the field is poised to do an even better job of slowing the relentless disease progression of Alzheimer’s disease. As we gear up for […]
Held annually in more than 600 communities nationwide, the Alzheimer’s Association Walk to End Alzheimer’s® is the world’s largest event to raise awareness and funds for Alzheimer’s care, support and research. Last month, Prothenians showed their support by participating in walks across the globe – including Dublin, San Francisco, San Diego, Philadelphia and Boston. As […]
Over 25 Prothenians attended the 16th annual Clinical Trials on Alzheimer’s Disease (CTAD) meeting in October in Boston, Massachusetts. As always, it was inspiring to join experts in the space to discuss the latest advances in Alzheimer’s disease R&D as we work toward a shared goal of delivering better treatments to patients. Throughout the year […]
Today, World Amyloidosis Day, we recognize people living with AL amyloidosis and their caregivers for their unwavering strength. We recently sat down with Ingrid Sprinz, PhD, Senior Medical Director, Hematology, to speak about current needs in the treatment of AL amyloidosis and Prothena’s progress in the space. Check out her perspective below. Q: What […]
“I want my kidneys biopsied.” In this powerful video, we hear about the journey to diagnosis from Linda, a daughter, mother and wife living with AL amyloidosis. After fifteen symptoms materialized over the course of just two years, Linda knew something wasn’t right. From severe back pain, sudden high blood pressure and uncontrollable vomiting, to […]
Like what you see? If you want to learn more about opportunities to join the #ProthenaProud team, check out our careers page here.
Tomorrow, August 26, marks Women’s Equality Day, but each day we are proud of the women who work to advance science and truly impact patient lives. We recently had the chance to hear from Ria Palarca and Nhu Truong on the importance of equal opportunity and a supportive workplace. Check out their perspectives below. […]
The Alzheimer’s disease space continues to buzz with news – advancements in the science and understanding of the disease, availability of new treatment options, and a newfound sense of hope for the Alzheimer’s community. In a recent interview with PharmaVoice, Prothena CEO Gene Kinney shares, “Science is an iterative process, and for a disease as […]
In this inspiring video, we hear how Mike’s amyloidosis has affected not only him, but his wife Donna and their marriage, too. In fact, they actually agree the diagnosis has brought them closer. Like many diseases, it is important to remember that amyloidosis changes the lives of more than just the patient. Donna, Mike’s primary […]
Throughout the last year, we’ve seen some of the most significant breakthroughs to date in Alzheimer’s disease research, most notably—solidifying that anti-Aβ is a viable and clinically-sound treatment pathway. This is only the beginning, and we at Prothena are both proud and excited to be a part of developing the next generation of therapies for […]
Prothena is working to develop new treatments for people facing some of the world’s most devastating diseases, including neurodegenerative diseases like Alzheimer’s and Parkinson’s. It’s a challenging mission that attracts people who are passionate and committed including Francisco Lio, our Senior Director, Global Program Manager, who manages interdisciplinary teams responsible for two promising Alzheimer’s […]
Like what you see? If you want to learn more about opportunities to join the #ProthenaProud team, check out our careers page here.
Q: Why is Prothena partnering with Walgreens? A: Our collaboration with Walgreens should accelerate patient identification and increase access and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial, which is evaluating the safety and tolerability of PRX012. PRX012 is a potential best-in-class anti-Aβ antibody under development for the treatment of Alzheimer’s disease […]
Prothena recently joined the Rare Disease Company Coalition, a coalition of companies dedicated to discovering, developing, and delivering rare disease treatments for the patients we collectively serve. “We are happy to welcome Prothena to the Coalition; they join us in our work to advocate for policies that enable positive changes to be realized for the […]
Q: What is ASPIRE? A: The Amyloidosis Stakeholder Partnerships for Impact Reach and Equity (ASPIRE) is a collaborative of biotech and pharmaceutical companies committed to improving diagnosis, systems of care, and health equity for patients suffering from amyloidosis, a rare disease caused by protein build-up. Q: What is ASPIRE’s goal? A: ASPIRE aims to accelerate […]